Janet Gardner, RPN Registered Nurse - Psych/Mental Health, Adult Medicare: Not Enrolled in Medicare Practice Location: Preferred Behavioral Health, 700 Airport Road, Lakewood, NJ 08701 Phone: 732-367-4700 Fax: 732-364-2253 |
Mrs. Karen Valerie Balsamo, Registered Nurse - Diabetes Educator Medicare: Not Enrolled in Medicare Practice Location: 700 Airport Rd, Lakewood, NJ 08701 Phone: 732-367-4700 Fax: 732-364-4190 |
Mr. Avrohom J Rothstein, RN Registered Nurse - Emergency Medicare: Not Enrolled in Medicare Practice Location: 159 Forest Park Cir, Lakewood, NJ 08701 Phone: 718-650-1155 |
Sarah Turk, Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 685 River Ave Unit 3, Lakewood, NJ 08701 Phone: 732-486-7373 |
Irene Osipenko, APN Registered Nurse Medicare: Medicare Enrolled Practice Location: 101 2nd St, Lakewood, NJ 08701 Phone: 732-363-6655 Fax: 732-901-0277 |
Kaitlin Rodriguez, APN Registered Nurse Medicare: Medicare Enrolled Practice Location: 101 2nd St, Lakewood, NJ 08701 Phone: 732-363-6655 Fax: 732-901-0277 |
Loredana Mezle, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 963 Ocean Ave, Lakewood, NJ 08701 Phone: 732-367-7444 Fax: 732-606-8201 |
Linda Obiamaka Okose, NP Registered Nurse - General Practice Medicare: Not Enrolled in Medicare Practice Location: 13 Buttell Ave, Lakewood, NJ 08701 Phone: 732-939-3041 Fax: 732-930-6027 |
News Archive
bioTheranostics, a bioMerieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announces the launch of an expanded tumor-type database for its flagship product, CancerTYPE IDĀ®, and the launch of KRAS mutational testing.
Disrupting sleep-wake cycles from a predominantly daytime to a delayed eating lifestyle, - i.e., skipping breakfast and making lunch the first meal of the day, plus eating late dinner, disrupts the body's natural circadian (24-hour) rhythm, the cycle that tells us when to sleep, wake up, eat, and influences hormones and other functions.
The number of alterations detected in the DNA collected from blood samples (liquid biopsies) of cancer patients treated with immune checkpoint inhibitors was associated with response to the treatment.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Schering-Plough's brain tumor treatment TemodarĀ® (temozolomide). The Court found that U.S. Patent No. 5,260,291 is not enforceable due to prosecution laches and inequitable conduct.
› Verified 6 days ago